arrow
J

Johanna Oechtering

university of basel
H指数:20
被引数:1,877

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Emerging CSF and Serum Biomarkers in Multiple Sclerosis

多发性硬化中新兴的脑脊液和血清生物标志物

2026-05-010
PRE
Serum GFAP and NfL augment a metabolomics-driven strategy for long-term prediction of multiple sclerosis progression

血清GFAP和NfL增强了代谢组学驱动的长期预测多发性硬化进展的策略

2026-02-250
OAAI
Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls

血清GFAP作为多发性硬化进展的生物标志物:检测试剂盒比较和健康对照组的大型参考数据库

2025-12-010
PRE
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response

血清神经丝轻链在多发性硬化中的研究:年龄和BMI校正的Z分数/百分位数对预测治疗反应优于绝对截断值

2025-08-030
OAAI
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort

特立氟胺和奥瑞利珠单抗对多发性硬化潜隐性活动比较效果:一项在瑞士多发性硬化队列中的观察性研究

2025-07-020
OAAI
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study

基于血清神经丝轻链在多发性硬化临床应用中的个性化治疗决策算法:一项改良德尔菲研究

2025-04-280
PRE
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis
2025-03-010
PRE
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort

瑞士多发性硬化队列中开始使用B细胞耗竭疗法患者的治疗持续性与临床结局

2025-02-260
OA
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis

血清胶质纤维酸性蛋白和神经丝轻链水平反映了多发性硬化b细胞耗竭治疗下疾病进展的不同机制

2024-10-164
OA
Complement Activation Is Associated With Disease Severity in Multiple Sclerosis
2024-03-018
OA
Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS
2024-01-0923
OAAI
Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5
BRAIN
IF11.7
2023-12-202
OAAI
Serum Glial Fibrillary Acidic Protein compared with Neurofilament Light Chain as Biomarker for Multiple Sclerosis Disease Progression
2023-04-250
PRE
Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis
2023-04-194
OAAI
Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study

严重的神经-COVID与外周免疫特征,自身免疫和神经变性有关: 一项前瞻性横断面研究

2022-11-0950
OAAI
Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS

鞘内IgM合成与早期MS的脊髓表现和神经元损伤有关

2022-04-099
OAAI
Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis
2021-06-2222
OAAI
Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
2021-05-0152
OAAI